Artal Group S.A. Tricida, Inc. Transaction History

Artal Group S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$8.56 - $26.93 $2.44 Million - $7.68 Million	-285,000 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$21.21 - $31.55 $1.59 Million - $2.37 Million	-75,000 Reduced 20.83%	285,000 $7.83 Million
Q2 2019 Aug 09, 2019	BUY	$31.16 - $39.46 $4.21 Million - $5.33 Million	135,000 Added 60.0%	360,000 $14.2 Million
Q1 2019 May 10, 2019	BUY	$19.96 - $38.62 $2 Million - $3.86 Million	100,000 Added 80.0%	225,000 $8.69 Million
Q4 2018 Feb 11, 2019	BUY	$23.57 - $32.33 $589,250 - $808,250	25,000 Added 25.0%	125,000 $2.95 Million
Q2 2018 Aug 10, 2018	BUY	$26.0 - $29.9 $2.6 Million - $2.99 Million	100,000 New	100,000 $2.99 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.